PI3K/Akt信号通路调节了参与抗癌免疫治疗耐药性的CD155表达
Katsushige Kawase1, Shusuke Kawashima2, Tatsuya Nishi3
1Chiba Cancer Center, Chiba-shi, Chiba, Japan.
Cancer immunology research
|July 31, 2025
概括
对PD-1阻断疗法的耐药性是一个挑战. 这项研究确定了双特异性氨酸-酸酸化调节激酶1A (DYRK1A) 和PI3K/Akt信号作为CD155表达的关键调节者,提供了克服癌症治疗耐药性的潜在策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 反编程死亡1 (PD-1) /PD-1连接体1单克隆抗体是有效的癌症治疗方法.
- 对这些疗法的耐药性是一个重大的临床问题.
- 具有Ig和ITIM域 (TIGIT) /CD155轴的T细胞免疫受体与治疗耐药性有关,但CD155调控尚未完全理解.
研究的目的:
- 为了确定调节CD155表达的关键分子.
- 研究这些调节器在瘤微环境 (TME) 中调节CD155中的作用.
- 探索克服PD-1阻塞抗性的治疗策略.
主要方法:
- 集群定期间隔的平行体重复 (CRISPR) 查以确定CD155调节者.
- 通过CRISPR/CRISPR相关蛋白9 (Cas9) 技术和用于基因/蛋白质抑制的DYRK1A抑制剂.
- 在头支状细胞癌 (HNSCC) 细胞系和患者样本中分析PI3K/Akt信号通路.
主要成果:
- 双特异性氨酸-酸酸化调节激酶1A (DYRK1A) 被确定为CD155表达的关键调节者.
- 抑制DYRK1A或针对PI3K/Akt的信号传递减少了CD155表达,并减轻了PD-1阻断抵抗.
- 在HNSCC患者中,CD155表达与Akt酸化和PD-1阻塞抵抗相关,特别是在高CD8+T细胞透的瘤中.
结论:
- PI3K/Akt信号通路在调节CD155表达方面发挥着至关重要的作用.
- 向DYRK1A或PI3K/Akt通路可以克服PD-1阻塞抵抗.
- 这些发现对于具有炎症TME和高CD155表达的癌症尤为重要.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Interactions Between Signaling Pathways
6.5K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.5K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K


